List of Excipients in Branded Drug ALOCRIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ALOCRIL	nedocromil sodium	0023-8842	BENZALKONIUM CHLORIDE
Allergan Inc	ALOCRIL	nedocromil sodium	0023-8842	EDETATE DISODIUM
Allergan Inc	ALOCRIL	nedocromil sodium	0023-8842	SODIUM CHLORIDE
Allergan Inc	ALOCRIL	nedocromil sodium	0023-8842	WATER

ALOCRIL Excipient Strategy and Commercial Opportunities for Nedocromil Sodium Ophthalmic Solution

Last updated: August 9, 2026

Alocril is a 2% nedocromil sodium ophthalmic solution for seasonal allergic conjunctivitis. Its formulation uses benzalkonium chloride, edetate disodium, sodium chloride, purified water, and pH-adjusting agents. The strongest commercial opportunities are preservative-free delivery, multidose packaging, improved ocular comfort, and regional generic or 505(b)(2) development rather than new-molecule exclusivity. The original compound and product-cycle protections are mature, and no biosimilar pathway applies.

What is Alocril and how is it formulated?

Alocril contains nedocromil sodium at 2%, equivalent to 20 mg/mL of nedocromil. The labeled dose is one drop in each affected eye twice daily. The product is indicated for the treatment of seasonal allergic conjunctivitis in adults and children aged three years and older.[1]

The FDA labeling identifies the following formulation components:

Component	Function
Nedocromil sodium	Active pharmaceutical ingredient
Benzalkonium chloride, 0.01%	Antimicrobial preservative
Edetate disodium	Chelating agent and preservative-support excipient
Sodium chloride	Tonicity adjustment
Sodium hydroxide and hydrochloric acid	pH adjustment
Purified water	Vehicle

The product is an aqueous sterile ophthalmic solution. The formulation does not depend on a complex suspension, emulsion, depot system, or device-mediated release mechanism. That reduces manufacturing complexity but leaves room for differentiated delivery systems.

What are the main formulation constraints?

Nedocromil sodium is highly water-soluble, so the principal development risks are not API solubilization and crystal control. The more relevant constraints are:

• Sterility throughout shelf life and in-use storage.
• Control of pH and osmolality for ocular tolerability.
• Preservative efficacy in multidose packaging.
• Compatibility between benzalkonium chloride and container surfaces.
• Ocular-surface exposure to preservatives during chronic or repeated seasonal use.
• Dose reproducibility from low-volume ophthalmic drops.
• Chemical stability under light, heat, and repeated container opening.

A generic developer can generally target a simple aqueous solution. A premium product needs a clinically meaningful excipient or packaging advantage.

What excipients are used in Alocril?

The legacy Alocril strategy is a conventional preserved ophthalmic solution. Benzalkonium chloride provides antimicrobial protection, while edetate disodium can improve preservative performance by binding divalent metal ions and reducing microbial resistance mechanisms.

What is the role of benzalkonium chloride?

Benzalkonium chloride is effective and widely used in ophthalmic products, but repeated exposure can disrupt the tear film, affect epithelial cells, and worsen ocular-surface symptoms in susceptible patients. These issues create the clearest opportunity for a preservative-free or reduced-preservative successor.

A preservative-free product would need a container-closure system that maintains sterility without relying on benzalkonium chloride. Commercial options include:

• Unit-dose polyethylene or polypropylene ampoules.
• Multidose bottles with one-way valves.
• Airless dispensing systems.
• Preservative-free pump systems.
• Sterile blow-fill-seal containers.

The commercial tradeoff is cost. Unit-dose formats increase packaging and logistics expense. Multidose preservative-free systems improve convenience but require more complex device qualification and extractables and leachables testing.

What is the role of edetate disodium?

Edetate disodium can support preservative efficacy and formulation robustness. In a preservative-free product, its role would need to be reassessed. Removing it may simplify the excipient profile, but it could alter metal-ion control, stability, or container compatibility.

A reformulation should not retain edetate automatically. Its continued use should be supported by stability, antimicrobial, and ocular-tolerability data.

What formulation patents could protect an improved Alocril product?

The strongest patent opportunities would relate to a new delivery system or clinically relevant formulation performance, not the basic nedocromil solution.

Preservative-free formulations

A patent could target:

• A specific nedocromil concentration and pH range.
• A defined osmolality range.
• A preservative-free multidose package.
• A particular valve or pump architecture.
• Stability after repeated actuation.
• Reduced microbial ingress.
• Reduced ocular irritation.
• A combination of formulation and container features.

A claim limited to removing benzalkonium chloride would face a novelty and obviousness challenge unless paired with a non-obvious packaging architecture or demonstrated stability benefit.

Comfort-oriented formulations

Potential excipient platforms include:

• Hydroxypropyl methylcellulose.
• Hypromellose.
• Polyvinyl alcohol.
• Polyethylene glycol.
• Propylene glycol.
• Hyaluronic acid or sodium hyaluronate.
• Polyquaternium-based preservative systems.
• Borate or phosphate buffering systems.

Viscosity-enhancing polymers may increase ocular residence time and reduce drop runoff. They can also cause blur, increase drop-string formation, complicate filtration, and affect dose delivery. Any patent strategy should link the polymer level to measurable performance, such as residence time, comfort, or reduced dosing frequency.

Combination products

A nedocromil product combined with a lubricant could target patients with both allergic conjunctivitis and ocular-surface discomfort. The regulatory and patent case would depend on showing more than simple co-administration. A fixed combination could be commercially attractive, but it would require compatibility, preservative, sterility, and clinical-use justification.

What is the FDA regulatory status of Alocril?

Alocril was approved by FDA under NDA 020955 as a prescription ophthalmic product.[1] Public FDA drug records identify the product as discontinued in the United States. Discontinuation is not equivalent to withdrawal for safety or efficacy reasons; FDA’s discontinued status is an administrative and commercial classification.[2]

Regulatory item	Alocril status
Active ingredient	Nedocromil sodium
Dosage form	Ophthalmic solution
Strength	2%
FDA pathway	NDA
Indication	Seasonal allergic conjunctivitis
Prescription status	Prescription ophthalmic product
Biosimilar pathway	Not applicable
Current U.S. commercial status	Discontinued listing in FDA records
Reference product relevance	Must be confirmed against current Orange Book and FDA records before an ANDA filing

A developer seeking to reintroduce the product must establish the appropriate regulatory reference and determine whether an approved reference product remains available for ANDA purposes. If a conventional ANDA pathway is unavailable or unsuitable, a 505(b)(2) strategy may be considered for a materially different formulation, dosage form, device, or dosing regimen.[3]

What is the Orange Book and patent status of Alocril?

The relevant intellectual-property estate is likely mature. Nedocromil sodium was developed decades ago, and basic compound, composition, and ophthalmic-use patents would generally have expired or reached the end of their commercial lives in the United States.

The current commercial questions are:

1. Whether any patent is listed for the relevant reference product.
2. Whether a formulation or method-of-use patent remains listed.
3. Whether an applicant would need a Paragraph IV certification.
4. Whether a discontinued NDA can support an ANDA reference strategy.
5. Whether any device or packaging patent is controlled by a third party.

A Paragraph IV challenge would be commercially meaningful only if an unexpired Orange Book patent is listed against an eligible reference product. If no relevant unexpired patent is listed, the applicant would not face the same patent-certification barrier, although non-Orange Book patents could still create litigation risk.

When does Alocril lose exclusivity?

The practical answer is that Alocril’s original exclusivity period has expired. The key barrier is no longer basic regulatory exclusivity. A new applicant’s risk is more likely to arise from reference-product availability, formulation differentiation, manufacturing qualification, and market access.

No biosimilar exclusivity analysis applies because nedocromil sodium is a small-molecule drug, not a biologic.

What generic entry opportunities exist for nedocromil ophthalmic products?

A conventional generic could reproduce the 2% aqueous solution and preserved multidose format. Its advantages would be low development complexity and familiar manufacturing controls. Its disadvantages would include limited differentiation and competition from newer allergy products.

A differentiated product could pursue one of four strategies:

Strategy	Value proposition	Main barrier
Preservative-free unit dose	Better ocular-surface profile	Higher packaging cost
Preservative-free multidose	Convenience with reduced preservative exposure	Device qualification
Comfort-enhanced solution	Improved patient experience	Clinical proof and formulation complexity
Extended-residence formulation	Potentially lower runoff or dosing burden	Blur, tolerability, and regulatory evidence

The most defensible commercial position is likely a preservative-free multidose product supported by robust microbial ingress data and a patient-use benefit.

How does Alocril compare with competing allergy eye drops?

Nedocromil competes with antihistamine, mast-cell stabilizer, and dual-action products. Many newer products offer once-daily dosing, faster symptom relief, or stronger brand recognition.

Product category	Representative active ingredients	Typical competitive advantage
Nedocromil	Nedocromil sodium	Mast-cell stabilization; established mechanism
Cromolyn	Cromolyn sodium	Longstanding mast-cell stabilizer
Dual-action agents	Olopatadine, ketotifen, alcaftadine, bepotastine	Antihistamine plus mast-cell activity
Lubricant products	Carboxymethylcellulose, polyethylene glycol, hyaluronic acid	Ocular-surface comfort
Corticosteroid products	Loteprednol and others	Greater anti-inflammatory activity, higher risk profile

A generic nedocromil product would need a price advantage or a specific tolerability and packaging position. A premium product would face difficulty competing on efficacy alone unless supported by comparative clinical data.

Which licensing and commercial opportunities are available?

The most realistic opportunities are product and technology transactions rather than licensing the original active ingredient.

Potential licensing targets

• Preservative-free ophthalmic packaging.
• Sterile multidose valve systems.
• Blow-fill-seal manufacturing capacity.
• Ocular-surface compatible polymers.
• Regional rights for nedocromil products.
• Contract manufacturing for sterile ophthalmic solutions.
• Drug-device combinations with validated microbial protection.

A company holding a sterile ophthalmic platform could use nedocromil as a lower-risk launch product before applying the same delivery system to antihistamines, prostaglandins, or dry-eye products.

Geographic opportunity

The commercial case differs by region. In the United States, the main question is regulatory reference-product strategy and reimbursement. In Europe and other markets, the opportunity may depend on local generic registration, existing national authorizations, and availability of the branded product.

A regional launch can be attractive where:

• Seasonal allergy prevalence is high.
• Preservative-free ophthalmic products command a premium.
• Generic competition is limited.
• Local registration can rely on an established product dossier.
• Sterile ophthalmic manufacturing capacity is scarce.

What manufacturing and IP barriers affect an Alocril successor?

The API is not the main barrier. Sterile manufacturing and container performance are more important.

Critical controls include:

• API identity, assay, impurities, and particle control.
• Sterile filtration or validated aseptic processing.
• Container-closure integrity.
• Preservative effectiveness testing where applicable.
• In-use stability.
• Drop-size consistency.
• Extractables and leachables.
• Photostability and temperature stability.
• Microbial ingress for multidose devices.

A product with a proprietary dispensing system may create freedom-to-operate issues even if the drug formulation is old. Device patents, trade secrets, and manufacturing know-how can remain commercially relevant after API patents expire.

What generic launch scenarios exist for Alocril?

Three launch scenarios are commercially plausible:

1. A low-cost preserved generic using the legacy formulation.
2. A preservative-free unit-dose product positioned for sensitive or chronic users.
3. A preservative-free multidose product positioned as a branded generic or 505(b)(2) product.

The first scenario has the lowest technical risk but the weakest differentiation. The third has the highest commercial upside and the greatest development burden. A successful launch would likely require a clear reimbursement, pharmacy, or specialist-prescribing strategy because competing allergy products may offer once-daily dosing.

Key Takeaways

• Alocril is a 2% nedocromil sodium ophthalmic solution for seasonal allergic conjunctivitis.
• Its legacy excipient system uses benzalkonium chloride, edetate disodium, sodium chloride, pH adjusters, and purified water.
• The strongest formulation opportunity is a preservative-free multidose or unit-dose product.
• Basic nedocromil composition and use patents are mature; current Orange Book and reference-product status must control any filing strategy.
• No biosimilar pathway applies.
• A conventional generic would be technically straightforward but commercially undifferentiated.
• Packaging, sterile manufacturing, ocular comfort, and device IP are more important barriers than API chemistry.
• A 505(b)(2) strategy may be relevant for a new preservative-free device, formulation, or dosing approach.
• Competitive pressure from olopatadine, ketotifen, alcaftadine, bepotastine, and lubricant products limits pricing power.
• The most attractive licensing targets are ophthalmic delivery platforms and sterile manufacturing capabilities.

FAQs

Can benzalkonium chloride be removed from Alocril without changing the active ingredient?

Yes. A preservative-free formulation can retain nedocromil sodium while changing the container and microbial-control strategy. The developer must establish sterility, in-use stability, container-closure integrity, and dose performance.

Is a preservative-free Alocril product automatically eligible for an ANDA?

No. Regulatory eligibility depends on the reference-product framework and the extent of formulation and device differences. A materially different product may require a 505(b)(2) application.

Can hyaluronic acid improve the commercial position of nedocromil eye drops?

Potentially. Hyaluronic acid may support ocular-surface comfort and residence time, but it can also alter viscosity, drop size, filtration, stability, and tolerability. The commercial case requires product-specific performance data.

Would an Alocril successor qualify for pediatric exclusivity?

Pediatric exclusivity is not automatic. It would require an FDA-issued written request and completion of the requested studies within the applicable statutory framework.

Is the main opportunity in Alocril the drug or the delivery system?

The delivery system. Nedocromil is an old, water-soluble small molecule. Commercial differentiation is more likely to come from preservative reduction, multidose sterility, ocular comfort, and device convenience.

References

1. U.S. Food and Drug Administration. (1999). Alocril (nedocromil sodium ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Alocril, NDA 020955.
3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Container closure systems for packaging human drugs and biologics.